The Innovative Medicines Initiative (IMI) has this week launched a new call for proposals. The latest call focuses on three key areas, namely: open access tools for the genetics of disease, optimising future obesity treatment and the environmental impacts of medicines.
The research on the new open access tools for the genetics of disease aims to develop a set of open access tools to facilitate the study of around 1,000 of the 3,000 genes thought to be implicated in disease and that could be targeted by drugs. The IMI says the results of the project will be made fully available to the scientific community by open access.
The obesity treatment topic aims to improve understanding of the disease by identifying sub-groups of people with obesity, which it says will ultimately pave the way for more personalised prevention and lifestyle interventions, as well as treatments for the disease and its complications. It will also focus on diabetes as an example of conditions that are influenced by obesity in a complex way.
The research on the environmental impacts of medicines will ultimately lead to the creation of a publicly available database to make environmental data on human medicinal products more transparent.
The total budget for the latest call is more than €80 million.